A novel anti‐inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

No abstract is available for this paper.

• Publication year

  1999

• Venue

  British Journal of Dermatology

• Publication date

  1999-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2133.1999.02974.xPMID 10468798
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The presence of IgE molecules on epidermal langerhans cells in patients with atopic dermatitis

  2004cited by this paper
• Characterization of grass pollen reactive T-cell lines derived from lesional atopic skin

  2004cited by this paper
• Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis.

  1998cited by this paper
• The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion

  1998cited by this paper
• Inhibition of Fc epsilon RI-mediated activation of mast cells by 2,3,4-trihydropyrimidino[2,1-a]isoquinolines.

  1998cited by this paper
• A novel human gene FKBP6 is deleted in Williams syndrome.

  1998cited by this paper
• A novel splice variant of the transcription factor Nrf1 interacts with the TNFalpha promoter and stimulates transcription.

  1998cited by this paper
• Inhibition of FcεRI-mediated activation of mast cells by 2,3,4-trihydropyrimidino[2,1-a]isoquinolines

  1998cited by this paper
• A novel anti‐inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology

  1997cited by this paper
• Differentiation of human dendritic cells from monocytes in vitro

  1997cited by this paper
• Immunofluorescence assay for the quantitative and qualitative evaluation of intracellular interleukin-8 in microtiter plates.

  1997cited by this paper
• Gene regulation after Fc epsilon RI stimulation in the murine mast cell line CPII.

  1997cited by this paper
• Correlation between dynamics and high affinity binding in an SH2 domain interaction.

  1996cited by this paper
• Induction of the TNF-alpha promoter in the murine dendritic cell line 18 and the murine mast cell line CPII is differently regulated.

  1996cited by this paper
• Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study.

  1996cited by this paper
• Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases.

  1996cited by this paper
• Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

  1995cited by this paper
• T cells involved in psoriasis vulgaris belong to the Th1 subset.

  1994cited by this paper
• Nonradioactive assay for protein phosphatase 2B (calcineurin) activity using a partial sequence of the subunit of cAMP-dependent protein kinase as substrate.

  1994cited by this paper
• Fetal skin-derived MHC class I+, MHC class II- dendritic cells stimulate MHC class I-restricted responses of unprimed CD8+ T cells.

  1994cited by this paper
• Peptidyl-prolyl cis/trans isomerases and their effectors

  1994cited by this paper
• Peptidyl‐Prolyl cis/trans Isomerases and Their Effectors

  1994cited by this paper
• Induction of IgE and IgG1 in human B cell cultures with staphylococcal superantigens: role of helper T cell interaction, resistance to interferon-gamma.

  1993cited by this paper
• Relative contributions of human types 1 and 2 T-helper cell-derived eosinophilotrophic cytokines to development of eosinophilia.

  1993cited by this paper
• The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response.

  1993cited by this paper
• Cyclosporine and its analogue SDZ IMM 125 mediate very similar effects on T-cell activation--a comparative analysis in vitro.

  1992cited by this paper
• Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis.

  1992cited by this paper
• The immunology of psoriasis

  1992cited by this paper
• In vivo Modulation of the High-Affinity Receptor for IgE (FcεRI) on Human Epidermal Langerhans Cells.

  1992cited by this paper
• Naturstoffe als Sonden zum Studium zellulärer Funktionen-Untersuchungen von Immunophilinen

  1992cited by this paper
• Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity.

  1992cited by this paper
• High frequency of IL-4-producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin.

  1991cited by this paper
• Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis.

  1991cited by this paper
• New colorimetric cytotoxicity assay for anticancer-drug screening.

  1990cited by this paper
• Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link.

  1990cited by this paper
• Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin.

  1990cited by this paper
• Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A.

  1990cited by this paper
• Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment.

  1989cited by this paper
• Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line

  1988cited by this paper
• IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2.

  1988cited by this paper
• Epidermal T lymphocytes and HLA‐DR expression in psoriasis

  1984cited by this paper
• T‐cell subpopulations in the blood and skin of patients with psoriasis

  1984cited by this paper
• Immunocompetent cells in psoriasis

  1983cited by this paper
• Enzyme kinetics

  1975cited by this paper
• Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

  1973cited by this paper
• In vitro stimulation of murine spleen cells using a microculture system and a multiple automated sample harvester.

  1973cited by this paper
• The determination of enzyme inhibitor constants.

  1953cited by this paper

• Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs

  2025cites this paper
• Identification of novel compounds against Trypanosoma cruzi using AlphaFold structures

  2025cites this paper
• Unraveling the therapeutic landscape of approved non-peptide macrocycles

  2025cites this paper
• Topical Medications for Chronic Itch in Older Patients: Navigating a Pressing Need

  2025cites this paper
• Protein serine/threonine phosphatases in tumor microenvironment: a vital player and a promising therapeutic target

  2025cites this paper
• Advancing Treatment in Atopic Dermatitis: A Comprehensive Review of Clinical Efficacy, Safety, and Comparative Insights Into Corticosteroids, Calcineurin Inhibitors, and Phosphodiesterase-4 Inhibitors as Topical Therapies

  2024cites this paper
• Pimecrolimus protects neuron‐like SH‐SY5Y cells against anti‐inflammatory and anti‐oxidant effects of both microglial secretome and hydrogen peroxide

  2023cites this paper
• Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders

  2023cites this paper
• Ocular Surface Disease and Anti-Glaucoma Medications: Various features, Diagnosis, and Management Guidelines

  2022cites this paper
• The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials

  2022influential citation
• Break on through: The role of innate immunity and barrier defence in atopic dermatitis and psoriasis

  2022cites this paper
• Rigorous analysis of the interaction between proteins and low water-solubility drugs by qNMR-aided NMR titration experiments.

  2021cites this paper
• High-content Screen Identifies Cyclosporin A as a Novel ABCA3-specific Molecular Corrector.

  2021cites this paper
• Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs

  2020cites this paper
• Bioprocess and genetic engineering aspects of ascomycin production: a review

  2020cites this paper
• Isolation of maltol derivatives from Stellera chamaejasme and the anti-atopic properties of maltol on skin lesions in DNCB-stimulated mice

  2019cites this paper
• Current and emerging therapies for hand eczema

  2019cites this paper
• Revisiting the Concept of Targeting NFAT to Control T Cell Immunity and Autoimmune Diseases

  2018cites this paper
• A new flavonoid from Stellera chamaejasme L., stechamone, alleviated 2,4‐dinitrochlorobenzene‐induced atopic dermatitis‐like skin lesions in a murine model

  2018cites this paper
• The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition

  2018cites this paper
• Cytokines: the yin and yang of vitiligo pathogenesis

  2018cites this paper
• Treatment of Atopic Dermatitis From the Perspective of Traditional Persian Medicine

  2017cites this paper
• Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review

  2017cites this paper
• Ligand Based-Pharmacophore Modeling and Extended Bi oactivity Prediction for Salinosporamide A, B and C from Marine Actino mycetes Salinispora tropica.

  2017cites this paper
• Pimecrolimus increases the expression of interferon-inducible genes that modulate human coronary artery cells proliferation.

  2016cites this paper
• The Role of Nerve Growth Factor in Atopic Dermatitis and the Modulation Effect of Pimecrolimus

  2016cites this paper
• Randomized controlled studies on the efficacy of antiarthritic agents in inhibiting cartilage degeneration and pain associated with progression of osteoarthritis in the rat

  2016cites this paper
• Therapeutic effect of ethyl acetate extract from Asparagus cochinchinensis on phthalic anhydride-induced skin inflammation

  2016cites this paper
• Therapies to improve the cosmetic symptoms of atopic dermatitis.

  2016cites this paper
• Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial

  2015cites this paper
• Pimecrolimus Is a Potent Inhibitor of Allergic Reactions to Hymenopteran Venom Extracts and Birch Pollen Allergen In Vitro

  2015cites this paper
• Пимекролимус в лечении атопического дерматита у детей. Вопросы безопасности и эффективности. Опыт пятилетнего применения

  2015cites this paper
• The Use of Topical Calcineurin Inhibitors in Atopic Dermatitis

  2014cites this paper
• Topical Treatment of Hand Eczema: Calcineurin Inhibitors

  2014cites this paper
• In vitro antioxidant and anti-inflammatory effects of brewers' spent grain protein rich isolate and its associated hydrolysates

  2013cites this paper
• Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm.

  2013cites this paper
• Topical pimecrolimus 1% cream in the treatment of seborrheic dermatitis.

  2013cites this paper
• Topical Calcineurin Inhibitors and Lymphoma Risk: Evidence Update with Implications for Daily Practice

  2013cites this paper
• Topical pimecrolimus in the treatment of genital lichen sclerosus

  2013cites this paper
• Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema

  2013cites this paper
• Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis

  2012cites this paper
• Phenolic extracts of brewers' spent grain (BSG) as functional ingredients - assessment of their DNA protective effect against oxidant-induced DNA single strand breaks in U937 cells.

  2012cites this paper
• Clinical Management of Atopic Dermatitis

  2012cites this paper
• Natural Products and Dermatological Hypersensitivity Diseases

  2012cites this paper
• Management of sulfur mustard-induced chronic pruritus: a review of clinical trials

  2012influential citation
• RANDOMIZED TRIAL OF TACROLIMUS 0.1% OINTMENT VERSUS TRIAMCINOLONE ACETONIDE 0.1% PASTE IN THE TREATMENT OF ORAL PEMPHIGUS VULGARIS

  2012cites this paper
• Recent Advances in Treatment Strategies for Atopic Dermatitis

  2012cites this paper
• S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

  2012cites this paper
• Cytokine and Anti-Cytokine Therapies for Psoriasis and Atopic Dermatitis

  2012cites this paper
• Topical Pimecrolimus

  2012influential citation
• Topical application of tacrolimus prevents epidural fibrosis in a rat postlaminectomy model: histopathological and ultrastructural analysis.

  2011cites this paper
• Current treatment options in psoriasis: topical agents

  2011cites this paper
• Calcineurin inhibitors: status quo and perspectives

  2011cites this paper
• Topical therapies for pruritus.

  2011cites this paper
• The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes

  2011cites this paper
• Effects of pimecrolimus versus triamcinolone on Langerhans cells after UV exposure

  2011cites this paper
• S3‐Leitlinie zur Therapie der Psoriasis vulgaris Update 2011

  2011cites this paper
• Pimecrolimus 1% cream for oral erosive lichen planus: a 6‐week randomized, double‐blind, vehicle‐controlled study with a 6‐week open‐label extension to assess efficacy and safety

  2011cites this paper
• Guidelines to Management of Atopic Dermatitis

  2011cites this paper
• S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011

  2011cites this paper
• Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma

  2011cites this paper
• Chemistry of the immunomodulatory macrolide ascomycin and related analogues.

  2011cites this paper
• Mast cells as targets of pimecrolimus.

  2011cites this paper
• Efficacy and Safety of Pimecrolimus Cream 1% in Mild-to-Moderate Chronic Hand Dermatitis: A Randomized, Double-Blind Trial

  2010cites this paper
• Pimecrolimus Cream 1% for the Treatment of Papulopustular Eruption Related to Epidermal Growth Factor Receptor Inhibitors: A Case Series and a Literature Review of Therapeutic Approaches

  2010cites this paper
• Hand dermatitis/eczema: Current management strategy

  2010cites this paper
• Eosinphils increase sensory neuron branching

  2010cites this paper
• Effects of Ultraviolet A‐1 Radiation on Calcineurin Activity and Cytokine Production in (Skin) Cell Cultures †

  2010cites this paper
• Topical Pimecrolimus 1% Cream for Resistant Seborrheic Dermatitis of the Face

  2010cites this paper
• Spotlight on Topical Pimecrolimus in Pediatric Atopic Dermatitis

  2010cites this paper
• Efectos biológicos de los stents medicados en la circulación coronaria

  2010cites this paper
• Four cases of facial discoid lupus erythematosus successfully treated with topical pimecrolimus or tacrolimus.

  2010cites this paper
• Pimecrolimus Reduces Eosinophil Activation Associated with Calcium Mobilization

  2009cites this paper
• Immunosuppressants as Treatment for Atopic Dermatitis

  2009cites this paper
• Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild‐to‐moderate atopic dermatitis

  2009cites this paper
• Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A.

  2009cites this paper
• Topical Pimecrolimus

  2009cites this paper
• Impact of Topical Calcineurin Inhibitors on Quality of Life in Patients with Atopic Dermatitis

  2009cites this paper
• Do we really understand pimecrolimus?

  2009cites this paper
• Use of pimecrolimus to prevent epidural fibrosis in a postlaminectomy rat model.

  2009cites this paper
• Role of Topical Calcineurin Inhibitors in the Treatment of Seborrheic Dermatitis

  2009cites this paper
• Optimizing topical therapy for psoriasis

  2009cites this paper
• Pathophysiology of Pruritus

  2009cites this paper
• Combination of low-dosage cyclosporine and topical pimecrolimus in severe atopic dermatitis with chronic hepatitis B.

  2008cites this paper
• Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study

  2008cites this paper
• Topical therapy II: retinoids, immunomodulators, and others

  2008cites this paper
• Pimecrolimus cream 1% in erosive oral lichen planus— a prospective randomized double‐blind vehicle‐controlled study

  2008cites this paper
• Calcineurin activity and inhibition in skin and (epi)dermal cell cultures.

  2008cites this paper
• Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro.

  2008cites this paper
• Treatment with pimecrolimus cream 1% clears irritant dermatitis of the periocular region, face and neck

  2008cites this paper
• Hand dermatitis: current treatment options.

  2008cites this paper
• Topical calcineurin inhibitors

  2008cites this paper
• Immunology and Treatment of Atopic Dermatitis

  2008cites this paper
• Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor.

  2008cites this paper
• Diagnosis and Management of Common Dermatoses in Children: Atopic, Seborrheic, and Contact Dermatitis

  2008cites this paper
• Binding of Pimecrolimus and Tacrolimus to Skin and Plasma Proteins: Implications for Systemic Exposure after Topical Application

  2008influential citation
• Management of Atopic Dermatitis in the Pediatric Population

  2008cites this paper
• Topical Immune Response Modifiers: Antiinflammatories

  2008cites this paper
• Topical therapy in pediatric atopic dermatitis.

  2008cites this paper
• Sustained Efficacy and Safety of Pimecrolimus Cream 1% when Used Long‐term (up to 26 Weeks) to Treat Children with Atopic Dermatitis

  2008cites this paper